Given that ferroptosis-related therapies have emerged as promising anti-cancer treatment strategies, with several FDA-approved drugs already available, such as sorafenib, sulfasalazine, statins, and artemisinin [6, 47, 48], we believe that developing small-molecule drugs targeting the LAPTM4B-SLC7A11 axis holds significant clinical potential. The gene discussed is LAPTM4B; the disease is cancer.